证券代码：688319 证券简称：欧林生物 公告编号：2025-035 成都欧林生物科技股份有限公司 第七届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都欧林生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日以现场及通讯方式在公司会议室召开第七届董事会第二次会议（以下简称"本 次会议"）。经全体董事同意，本次会议豁免通知时限要求。本次会议由公司董 事长樊绍文先生召集并主持，应出席董事 9 人，实际出席会议董事 9 人。本次会 议的通知、召开及审议程序符合《中华人民共和国公司法》《上海证券交易所科 创板股票上市规则》等法律法规、规范性文件及《成都欧林生物科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议，本次会议通过如下议案： （一）审议通过了《关于调减公司以简易程序向特定对象发行股票募集资 金总额暨调整发行方案的议案》 根据《中华人民共和国证券法》《上市公司证券发行注册管理 ...

经审阅，我们认为：公司将本次发行募集资金总额由 17,529.29 万元调减为 12,529.29 万元，各发行对象获配数量和金额进行同比例调减，并相应调整本次 发行方案相关内容，符合公司实际情况以及相关法律法规、规范性文件的有关规 定及公司 2023 年年度股东大会、2024 年年度股东大会的授权。因此，我们一致 同意《关于调减公司以简易程序向特定对象发行股票募集资金总额暨调整发行方 案的议案》。 独立董事专门会议 2025 年第一次会议决议 一、独立董事专门会议召开情况 成都欧林生物科技股份有限公司（以下简称"公司"）第七届董事会独立董 事专门会议 2025 年第一次会议于 2025 年 8 月 18 日在公司会议室以现场及通讯 方式召开。本次会议由独立董事陈正旭先生主持，应出席独立董事 3 名，实际出 席独立董事 3 名。本次会议的召集和召开程序符合《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》的相关规定，会议决议合法有效。 二、独立董事专门会议审议情况 本着勤勉尽责、客观公正的原则，经与会独立董事审议，以投票表决方式通 过以下议案： （一）审议通过了《关于调减公司以简易程序向特定对 ...

（文章来源：每日经济新闻） 欧林生物8月18日晚间发布公告称，公司第七届2025年第一次董事会会议于2025年8月18日在公司会议室 以现场及通讯方式召开。会议审议了《关于公司以简易程序向特定对象发行股票方案的论证分析报告的 议案》等文件。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300841 | 康华生物 | 87.17 | -5.31% | 11.81万 | 10.31亿 | | 002773 | 康弘药业 | 44.40 | -3.48% | 11.20万 | 4.95 Z | | 000518 | *ST四环 | 2.26 | -0.88% | 14.93万 | 3374.66万 | | 600867 | 通化东宝 | 8.38 | -0.71% | 41.66万 | 3.51亿 | | 603590 | 康辰药业 | 56.63 | -0.46% | 6.32万 | 3.61亿 | | 000534 | 万泽股份 | 16.62 | -0.30% | 18.85万 | 3.13亿 | | 688520 | 神州细胞 | 73.00 | -0.27% | 11.67万 | 8.39亿 | | 600211 | 西藏药业 | 46.85 | -0.21% | 13.98万 | 6.55亿 | | 301166 | 优宁 ...

Core Viewpoint - Tianfeng Securities has issued a report on August 18, recommending a "buy" rating for Olin Bio (688319.SH) at a latest price of 23.99 yuan, highlighting the company's growth potential in the vaccine market [2] Group 1: Market Expansion - The tetanus vaccine is experiencing continuous growth in demand, leading to an expanding market size [2] - The development of the golden staphylococcus vaccine is globally leading, indicating a broad future market prospect [2] Group 2: Clinical Progress - The company has received approval for Phase 1 clinical trials for its Helicobacter pylori vaccine in Australia, marking a significant milestone in its research and development efforts [2]

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 300147 | ST香雪 | 1 | 16.47 | 58.92亿 | -8.80 | | 300199 | 翰宇药业 | 1 | 12.05 | 258亿 | 126.53 | | 002082 | 万邦德 | | 10.01 | 49.06亿 | 24.73 | | 600535 | 天士力 | 1 | 7.73 | 260亿 | 22.17 | | 688091 | 上海谊众 | નાર | 6.94 | 169亿 | 104.93 | | 688319 | 欧林生物 | | 5.63 | 103亿 | 139.06 | | 688621 | 阳光诺和 | 一座 | 5.22 | 90.33亿 | 114.56 | | 430047 | 诺思兰德 | -06 | 4.62 | 67.06 Z | 112.06 | | 300683 | 海特生物 | નહ | 4.08 | 75.41亿 | 143.08 | | 688189 | 南新制药 | 来 ...

Core Viewpoint - The report highlights the growth potential of Olin Biologicals, particularly in the tetanus vaccine market and the promising development of the pneumococcal vaccine, leading to a "Buy" rating with a target price of 27.09 yuan per share [1][6]. Group 1: Company Overview - Olin Biologicals is a biopharmaceutical company focused on the research, production, and sales of human vaccines, with key products including the adsorbed tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine [2]. - The adsorbed tetanus vaccine is the company's core product, contributing nearly 80% of revenue and maintaining a gross margin above 90% [3]. Group 2: Market Potential - The market for the adsorbed tetanus vaccine is expected to grow to 2.4 billion yuan by 2030, driven by supportive policies [3]. - The company is leading globally in the development of the recombinant pneumococcal vaccine, which is currently in Phase III clinical trials, with the potential to fill a significant market gap if successful [4]. Group 3: Research and Development Pipeline - In addition to the pneumococcal vaccine, the company has several other vaccine candidates in development, including oral recombinant Helicobacter pylori vaccine and recombinant Pseudomonas aeruginosa vaccine, all classified as first-in-class drugs [5]. - Successful development of the pneumococcal vaccine could enhance the company's reputation in the antibiotic-resistant vaccine sector and strengthen its long-term competitive position [5]. Group 4: Financial Projections - Revenue projections for the company from 2025 to 2027 are estimated at 647 million, 713 million, and 772 million yuan, respectively, with year-on-year growth rates of 9.80%, 10.27%, and 8.34% [6]. - Net profit attributable to shareholders is forecasted to be 30 million, 44 million, and 66 million yuan for the same period, with corresponding earnings per share of 0.07, 0.11, and 0.16 yuan [6].

Investment Rating - The report assigns an "Accumulate" rating for the company with a target price of 27.09 CNY per share, based on a 17x PS for 2025 [7]. Core Insights - The company focuses on human vaccine research, development, production, and sales, with a strong pipeline including the Tetanus vaccine and the promising Staphylococcus aureus vaccine [1][15]. - The Tetanus vaccine is the core product, contributing nearly 80% of revenue and maintaining a gross margin above 90% [2][23]. - The Staphylococcus aureus vaccine is in phase III clinical trials and is expected to fill a significant market gap if successful [3][4]. Summary by Sections Company Overview - The company has established itself in the human vaccine sector, with a clear focus on both traditional and innovative vaccine development [15]. - It has received multiple accolades, including "National Intellectual Property Advantage Enterprise" [15]. Tetanus Vaccine Market - The Tetanus vaccine market is projected to grow to 2.4 billion CNY by 2030, driven by increasing awareness and supportive policies [2][41]. - The vaccine's sales have shown significant growth, reaching 536 million CNY in 2024, accounting for approximately 91% of the company's revenue [45]. Staphylococcus Aureus Vaccine Development - The company is leading globally in the development of the Staphylococcus aureus vaccine, which addresses a critical need due to rising antibiotic resistance [3][49]. - The vaccine's potential market is vast, with applications expected to expand beyond orthopedic surgeries to other hospital-acquired infections [3][4]. Financial Projections - Revenue forecasts for 2025-2027 are 646.55 million CNY, 712.98 million CNY, and 772.43 million CNY, with respective growth rates of 9.80%, 10.27%, and 8.34% [5][6]. - Net profit attributable to shareholders is projected to be 29.73 million CNY, 44.37 million CNY, and 66.15 million CNY for the same period [5][6]. Research and Development - The company has a robust R&D pipeline, with multiple products in various stages of clinical trials, including the Helicobacter pylori vaccine [4][34]. - R&D expenses have been increasing, reflecting the company's commitment to innovation and development in the vaccine sector [27][28].

证券之星消息，8月13日生物制品板块较上一交易日上涨1.6%，欧林生物领涨。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688319 | 欧林生物 | 24.02 | 17.17% | 17.21万 | | 3.83亿 | | 688488 | 文迪药业 | 16.65 | 7.56% | 20.39万 | | 3.30亿 | | 688443 | 智翔金泰 | 35.15 | 6.97% | 10.04万 | | 3.43 Z | | 002773 | 康弘药业 | 44.49 | 5.48% | 10.18万 | | 4.47亿 | | 301080 | 百普赛斯 | 57.12 | 5.47% | 3.98万 | | 2.24亿 | | 688180 | 君实生物 | 43.46 | 5.03% | 23.94万 | | 10.25亿 | | ...

Market Overview - The Shanghai Composite Index closed at 3682.19 points, above the five-day moving average, with a gain of 0.44% [1] - The total trading volume of A-shares reached 171.88 billion yuan [1] Stocks Exceeding Five-Day Moving Average - A total of 620 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Shouyao Holdings (15.20%) - Zhongyi Technology (11.60%) - Olin Bio (10.16%) [1][2] Stock Performance Data - The following stocks showed the highest deviation rates from the five-day moving average: - Shouyao Holdings: Today's gain of 19.99%, turnover rate of 9.80%, latest price at 55.94 yuan [2] - Zhongyi Technology: Today's gain of 15.43%, turnover rate of 18.35%, latest price at 31.49 yuan [2] - Olin Bio: Today's gain of 12.73%, turnover rate of 2.99%, latest price at 23.11 yuan [2] - Other notable stocks include: - Guanggang Gas (9.92%) - Tianlong Group (9.55%) - Feilihua (9.54%) [2][3]